Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

March 8, 2022 updated by: AbbVie

A Phase 1, Pharmacokinetic Comparability Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Subjects

The primary objectives of this study are to assess the relative bioavailability of risankizumab in on-body delivery system (OBDS) versus the prefilled syringe (PFS) (Substudy 1) and to assess the relative bioavailability of risankizumab in the to-be-marketed Dose A liquid vial versus the Dose B liquid vial used in the Phase 3 studies (Substudy 2).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
394

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Anaheim, California, United States, 92801-2658
        • Anaheim Clinical Trials LLC /ID# 222821
      • Cypress, California, United States, 90630
        • Altasciences Clinical Los Angeles, Inc /ID# 222238
    • Florida
      • Miami, Florida, United States, 33014
        • Clinical Pharmacology of Miami /ID# 225392
      • Orlando, Florida, United States, 32806-1044
        • PPD Clinical Research Unit /ID# 222362
    • Illinois
      • Grayslake, Illinois, United States, 60030
        • Acpru /Id# 222349
    • Nevada
      • Las Vegas, Nevada, United States, 89113-2235
        • PPD Clinical Research Unit -Las Vegas /ID# 222363
    • Texas
      • Austin, Texas, United States, 78744
        • PPD Clinical Research Unit - Austin /ID# 222361
    • Wisconsin
      • West Bend, Wisconsin, United States, 53095
        • Spaulding Clinical Research LLC /ID# 225405

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

- Body weight less than 100.00 kg at Screening and upon initial confinement.

Exclusion Criteria:

- Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
EXPERIMENTAL: Group 1: Risankizumab Dose A
Participants will receive risankizumab dose A.
Drug: Risankizumab
Subcutaneous Injection via prefilled syringe (PFS)
Other Names:
  • SKYRIZI
Drug: Risankizumab
Intravenous Infusion
Other Names:
  • SKYRIZI
Drug: Risankizumab
Subcutaneous Injection via on-body delivery system (OBDS)
Other Names:
  • SKYRIZI
EXPERIMENTAL: Group 2: Risankizumab Dose B
Participants will receive risankizumab dose B.
Drug: Risankizumab
Subcutaneous Injection via prefilled syringe (PFS)
Other Names:
  • SKYRIZI
Drug: Risankizumab
Intravenous Infusion
Other Names:
  • SKYRIZI
Drug: Risankizumab
Subcutaneous Injection via on-body delivery system (OBDS)
Other Names:
  • SKYRIZI
EXPERIMENTAL: Group 3: Risankizumab Dose C
Participants will receive risankizumab dose C.
Drug: Risankizumab
Subcutaneous Injection via prefilled syringe (PFS)
Other Names:
  • SKYRIZI
Drug: Risankizumab
Intravenous Infusion
Other Names:
  • SKYRIZI
Drug: Risankizumab
Subcutaneous Injection via on-body delivery system (OBDS)
Other Names:
  • SKYRIZI
EXPERIMENTAL: Group 4: Risankizumab Dose D
Participants will receive risankizumab dose D.
Drug: Risankizumab
Subcutaneous Injection via prefilled syringe (PFS)
Other Names:
  • SKYRIZI
Drug: Risankizumab
Intravenous Infusion
Other Names:
  • SKYRIZI
Drug: Risankizumab
Subcutaneous Injection via on-body delivery system (OBDS)
Other Names:
  • SKYRIZI
EXPERIMENTAL: Group 5: Risankizumab Dose D
Participants will receive risankizumab dose D.
Drug: Risankizumab
Subcutaneous Injection via prefilled syringe (PFS)
Other Names:
  • SKYRIZI
Drug: Risankizumab
Intravenous Infusion
Other Names:
  • SKYRIZI
Drug: Risankizumab
Subcutaneous Injection via on-body delivery system (OBDS)
Other Names:
  • SKYRIZI

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Percentage of Participants Experiencing Adverse Events (AEs)
Time Frame: Up to approximately 140 days
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Up to approximately 140 days
Maximum Observed Serum Concentration (Cmax)
Time Frame: Up to approximately 113 days
Maximum observed serum concentration (Cmax) of risankizumab.
Up to approximately 113 days
Time to Cmax (Tmax)
Time Frame: Up to approximately 113 days
Time to Cmax of risankizumab.
Up to approximately 113 days
Apparent Terminal Phase Elimination Rate Constant (β)
Time Frame: Up to approximately 113 days
Apparent terminal phase elimination rate constant (β) of risankizumab.
Up to approximately 113 days
Terminal Phase Elimination Hhalf-life (t1/2)
Time Frame: Up to approximately 113 days
Terminal phase elimination half-life (t1/2) of risankizumab.
Up to approximately 113 days
Area Under Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt)
Time Frame: Up to approximately 113 days
AUCt of risankizumab.
Up to approximately 113 days
AUC From Time 0 to Infinity (AUCinf)
Time Frame: Up to approximately 113 days
AUCinf of risankizumab.
Up to approximately 113 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
AbbVie

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2020

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 6, 2021

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 6, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
March 8, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 8, 2022

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
March 10, 2022

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 10, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 8, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • M19-128

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings